ATAD1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This polyclonal pool harbors a heterogeneous disruption of the ATAD1 gene, leading to loss of functional ATAD1 protein expression. The CRISPR/Cas9-mediated gene disruption model provides a powerful tool for investigating the role of the mitochondrial AAA-ATPase ATAD1 in cellular homeostasis.
The parental A-549 cell line is a widely used model of human alveolar Type II epithelium, originally derived from a male patient with lung adenocarcinoma. These adherent epithelial cells exhibit characteristics of lung carcinoma, including abnormal proliferation and resistance to apoptosis, making them relevant for cancer biology and therapeutic development. The cell line’s robust growth properties facilitate genetic manipulation and downstream functional assays, enabling reproducible evaluation of gene function in a lung cancer context.
ATAD1 is a mitochondrial outer membrane AAA-ATPase that functions as a quality control enzyme, extracting mislocalized tail-anchored proteins and damaged substrates from the outer mitochondrial membrane for proteasomal degradation. It operates upstream of key mitochondrial dynamics proteins such as mitofusins Mfn1 and Mfn2 and the fission factor Drp1, and interacts with the Tomm import complex, VCP/p97, and ubiquitin ligases. Loss of ATAD1 leads to accumulation of aberrant outer membrane proteins, disrupting mitochondrial fission?Cfusion balance and sensitizing cells to apoptotic signals by facilitating cytochrome c release and caspase activation. The gene is transcriptionally regulated by mitochondrial stress responses, including the mitochondrial unfolded protein response, and in turn modulates the stability of outer membrane substrates like Fis1.
In A-549 polyclonal knockout cells, abrogation of ATAD1 function provides a platform to dissect mitochondrial proteostasis and dynamics specifically within lung adenocarcinoma. These cells enable characterization of how mitochondrial quality control loss impacts cancer cell survival under oxidative or therapeutic stress. The model is particularly relevant for studying the interplay between mitochondrial dysfunction and apoptotic resistance, a hallmark of many cancers, and can reveal vulnerabilities exploitable by mitochondrial-targeted therapies.
Researchers can employ these polyclonal knockout cells in a variety of assays, including western blotting for ATAD1 and its downstream targets Mfn1 and Mfn2, immunofluorescence to assess mitochondrial morphology, and apoptosis assays such as Annexin V staining or caspase-3/7 activity measurements. Further applications include measuring mitochondrial membrane potential with TMRE and profiling mitochondrial stress gene expression via RT-qPCR, as well as drug sensitivity screens to identify modulators of apoptosis. This model is suitable for investigations in mitochondrial biology, protein quality control, cancer cell stress responses, and drug resistance. For further details, please contact Ascent Research.
